The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are unsuitable for combination therapy, the Dana-Farber Cancer Institute announced on August 26, 2026. The drug by Revolution Medicines is marketed as Rasonque and represents, according to STAT News, the first treatment against a genetic driver of this aggressive cancer. The approval is based on the randomized, open-label Phase 3 trial RASolute 302, in which 500 patients were assigned 1:1 to receive either daraxonrasib or physician-selected standard chemotherapy, according to The ASCO Post. The trial enrolled patients with disease progression after exactly one prior systemic therapy line.
Among patients diagnosed with metastatic pancreatic cancer between 2015 and 2021, approximately 97 percent died within five years, The Conversation reported. This reflects the absence of effective early-detection tests and the fact that early stages rarely cause noticeable symptoms. By the time jaundice or abdominal pain appears, the cancer has often already spread. Pancreatic adenocarcinoma accounts for approximately 3.2 percent of all cancer diagnoses but causes a disproportionate share of cancer deaths, the FDA noted via ABC News, a pattern the agency attributes to late detection, aggressive disease progression, and historically limited treatment options. More than 90 percent of pancreatic tumors are driven by mutations in the KRAS gene, which codes for proteins that normally act as switches controlling cell growth but remain permanently switched on when mutated, The Conversation reported. For decades, scientists considered KRAS undruggable because its surface is unusually smooth and lacks the molecular pockets needed for typical drugs to bind.
How the tablet blocks the cancer switch
According to the trial registry, daraxonrasib is taken as an oral tablet. Rather than binding directly to KRAS, the active ingredient attaches to a molecule called cyclophilin A, which assists in protein folding. The resulting complex can then bind to active KRAS protein and block its signal for cancer cell multiplication, The Conversation explained.
What the approval trial showed
In the overall study population, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy (hazard ratio 0.40). Median progression-free survival was 7.2 months versus 3.6 months, and objective response rate was 30 percent versus 11 percent. The prescribing information lists warnings for skin and soft tissue toxicity, stomatitis, diarrhea, gastrointestinal perforation, interstitial lung disease, and embryofetal toxicity. The recommended dose is 300 milligrams once daily until disease progression or unacceptable toxicity. More than 86 percent of trial participants experienced a rash, and common side effects also included stomatitis, diarrhea, nausea, and vomiting, The Conversation reported. Patients discontinued treatment significantly less often due to severe adverse effects compared to chemotherapy and reported better quality of life and reduced pain, the article noted. These quality of life and pain assessments are qualitative observations from an open-label trial report. Dana-Farber study leader Brian Wolpin stressed the drug is not a cure. Most patients with metastatic disease eventually develop resistance, allowing cancer to progress despite treatment.
Compared to prior standard treatment
The trial comparison group received one of four established chemotherapy regimens per the protocol: gemcitabine plus nab-paclitaxel, modified FOLFIRINOX, liposomal irinotecan plus 5-fluorouracil, or FOLFOX. Oncologist Andrew Ko of the University of California, San Francisco, called the new therapy the biggest advance in pancreatic cancer treatment in decades, according to STAT News. Hornstein told CancerNetwork that daraxonrasib is the first effective systemic therapy for pancreatic cancer outside of chemotherapy and noted the approval does not require a RAS mutation.
Why the treatment is not a cure
Wolpin pointed to numerous ongoing studies investigating how pancreatic tumors develop resistance to daraxonrasib and other RAS-directed therapies. Identifying these mechanisms could form the basis for new counter-strategies. Revolution Medicines has built a development pipeline to investigate resistance mechanisms, according to Hornstein. The Conversation expected more clinical trials combining KRAS inhibitors such as daraxonrasib with other drugs to prevent resistance and further extend survival.